{
  "paper_id": "TCQSZRTJ",
  "abstract": "address CONSORT item 1a? * I.e does the title contain the phrase \"Randomized Controlled Trial\"? (if not, explain the reason under \"other\") 1a-i) Identify the mode of delivery in the title Identify the mode of delivery. Preferably use \"web-based\" and/or \"mobile\" and/or \"electronic game\" in the title. Avoid ambiguous terms like \"online\", \"virtual\", \"interactive\". Use \"Internet-based\" only if Intervention includes non-web-based Internet components (e.g. email), use \"computer-based\" or \"electronic\" only if o ine products are used. Use \"virtual\" only in the context of \"virtual reality\" (3-D worlds). Use \"online\" only in the context of \"online support groups\". Complement or substitute product names with broader terms for the class of products (such as \"mobile\" or \"smart phone\" instead of \"iphone\"), especially if the application runs on different platforms.",
  "doi": "10.2196/jmir.1923",
  "md5": "77C7CC54BDAC3678BC100A0C0D28C9EB",
  "keywords": [
    "comparator",
    "care providers",
    "centers",
    "and blinding status"
  ],
  "sections": [
    {
      "text": "Clarify the level of human involvement in the abstract, e.g., use phrases like \"fully automated\" vs. \"therapist/nurse/care provider/physician-assisted\" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it) Does your paper address subitem 1b-ii?\n\nCopy and paste relevant sections from the manuscript abstract (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer 1b-iii) Open vs. closed, web-based (self-assessment) vs. face-toface assessments in the METHODS section of the ABSTRACT Mention how participants were recruited (online vs. o ine), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Does your paper address subitem 1b-iii?\n\nCopy and paste relevant sections from the manuscript abstract (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer 1b-iv) RESULTS section in abstract must contain use data\n\nReport number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer 1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome -if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it) Does your paper address subitem 1b-v?\n\nCopy and paste relevant sections from the manuscript abstract (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer 2a-i) Problem and the type of system/solution\n\nDescribe the problem and the type of system/solution that is object of the study: intended as standalone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in \"Methods\" under 5) Does your paper address subitem 2a-i? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study"
    },
    {
      "title": "Objectives",
      "text": "The objectives of this study are to 1) examine the impact of a VR-based dietary mobile game, on actual and hypothetical food choices, 2) explore children's heterogeneous game play patterns, and 3) understand the effects of game mechanisms by associating game play patterns with players' actual food choices. Does your paper address subitem 2a-ii? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nThe \"Theoretical Background\" section.\n\nDoes your paper address CONSORT subitem 2b? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study"
    },
    {
      "title": "Objectives",
      "text": "The objectives of this study are to 1) examine the impact of a VR-based dietary mobile game, on actual and hypothetical food choices, 2) explore children's heterogeneous game play patterns, and 3) understand the effects of game mechanisms by associating game play patterns with players' actual food choices.\n\nDoes your paper address CONSORT subitem 3a? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nThe \"Experiment and data\" section.\n\nhttps://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2\u2026  11/33 subitem not at all important 1 2 3 4 5 essential 4a) Eligibility criteria for participants subitem not at all important 1 2 3 4 5 essential Does your paper address CONSORT subitem 3b? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study No. 3b-i) Bug xes, Downtimes, Content Changes Bug xes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug xes or changes in the functionality or content) (5-iii) and other \"unexpected events\" that may have in uenced study design such as staff changes, system failures/downtimes, etc. [2].\n\nDoes your paper address subitem 3b-i?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer Does your paper address CONSORT subitem 4a? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nThe \"Experiment and data\" section."
    },
    {
      "title": "4a-i) Computer / Internet literacy",
      "text": "Computer / Internet literacy is often an implicit \"de facto\" eligibility criterion -this should be explicitly clari ed.\n\nDoes your paper address subitem 4a-i?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2\u2026  12/33 subitem not at all important 1 2 3 4 5 essential subitem not at all important 1 2 3 4 5 essential 4b) Settings and locations where the data were collected subitem not at all important 1 2 3 4 5 essential 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:\n\nOpen vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. o ine), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email con rmation, phone calls) were used to detect/prevent these.\n\nDoes your paper address subitem 4a-ii? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nThe \"Experiment and data\" section."
    },
    {
      "title": "4a-iii) Information giving during recruitment",
      "text": "Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results."
    },
    {
      "title": "Does your paper address subitem 4a-iii?",
      "text": "Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer Does your paper address CONSORT subitem 4b? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nThe \"Experiment and data\" section."
    },
    {
      "title": "4b-i) Report if outcomes were (self-)assessed through online questionnaires",
      "text": "Clearly report if outcomes were (self-)assessed through online questionnaires (as common in webbased trials) or otherwise.\n\nhttps://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2\u2026  13/33\n\nsubitem not at all important Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nThe \"Experiment and data\" section."
    },
    {
      "title": "4b-ii) Report how institutional a liations are displayed",
      "text": "Report how institutional a liations are displayed to potential participants [on ehealth media], as a liations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item -describe only if this may bias results) Does your paper address subitem 4b-ii?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer 5-i) Mention names, credential, a liations of the developers, sponsors, and owners Mention names, credential, a liations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a \"Con ict of interest\" section or mentioned elsewhere in the manuscript).\n\nDoes your paper address subitem 5-i?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer 5-ii) Describe the history/development process Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.\n\nhttps://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2\u2026  14/33\n\nsubitem not at all important Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer"
    },
    {
      "title": "5-iii) Revisions and updating",
      "text": "Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was \"frozen\" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).\n\nDoes your paper address subitem 5-iii?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer"
    },
    {
      "title": "5-iv) Quality assurance methods",
      "text": "Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.\n\nDoes your paper address subitem 5-iv?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer 5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing owcharts of the algorithms used Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing owcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scienti c reporting. https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2\u2026  15/33 subitem not at all important 1 2 3 4 5 essential subitem not at all important 1 2 3 4 5 essential Does your paper address subitem 5-v?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer"
    },
    {
      "title": "5-vi) Digital preservation",
      "text": "Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.\n\nDoes your paper address subitem 5-vi?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer"
    },
    {
      "title": "5-vii) Access",
      "text": "Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of speci c group. If known, describe how participants obtained \"access to the platform and Internet\" [1]. To ensure access for editors/reviewers/readers, consider to provide a \"backdoor\" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).\n\nDoes your paper address subitem 5-vii? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nThe \"Experiment and data\" section.\n\nhttps://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2\u2026  16/33 subitem not at all important 1 2 3 4 5 essential subitem not at all important 1 2 3 4 5 essential subitem not at all important 1 2 3 4 5 essential 5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1],\" whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback\" [6]. This also includes a description of communication delivery channels and -if computer-mediated communication is a component -whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].\n\nDoes paper address subitem 5-viii? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nThe \"The Intervention\" section."
    },
    {
      "title": "5-ix) Describe use parameters",
      "text": "Describe use parameters (e.g., intended \"doses\" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum."
    },
    {
      "title": "Does your paper address subitem 5-ix?",
      "text": "Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study Your answer"
    },
    {
      "title": "5-x) Clarify the level of human involvement",
      "text": "Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as \"type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered\". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21generalizability).\n\nhttps://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2\u2026  17/33\n\nsubitem not at all important 1 2 3 4 5 essential subitem not at all important 1 2 3 4 5 essential 6a) Completely de ned pre-speci ed primary and secondary outcome measures, including how and when they were assessed Does your paper address subitem 5-x?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study Your answer"
    },
    {
      "title": "5-xi) Report any prompts/reminders used",
      "text": "Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 -generalizability)."
    },
    {
      "title": "Does your paper address subitem 5-xi? *",
      "text": "Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nNo."
    },
    {
      "title": "5-xii) Describe any co-interventions (incl. training/support)",
      "text": "Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 -generalizability."
    },
    {
      "title": "Does your paper address subitem 5-xii? *",
      "text": "Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nNo.\n\nDoes your paper address CONSORT subitem 6a? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nThe \"Methods\" section.\n\nsubitem not at all important Does your paper address subitem 6a-i?\n\nCopy and paste relevant sections from manuscript text\n\nYour answer 6a-ii) Describe whether and how \"use\" (including intensity of use/dosage) was de ned/measured/monitored Describe whether and how \"use\" (including intensity of use/dosage) was de ned/measured/monitored (logins, log le analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial."
    },
    {
      "title": "Does your paper address subitem 6a-ii?",
      "text": "Copy and paste relevant sections from manuscript text\n\nYour answer 6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).\n\nDoes your paper address subitem 6a-iii?\n\nCopy and paste relevant sections from manuscript text Your answer  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2\u2026  19/33 7a) How sample size was determined NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed subitem not at all important 1 2 3 4 5 essential 7b) When applicable, explanation of any interim analyses and stopping guidelines 8a) Method used to generate the random allocation sequence NPT: When applicable, how care providers were allocated to each trial group Does your paper address CONSORT subitem 6b? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nNo.\n\n7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size Describe whether and how expected attrition was taken into account when calculating the sample size.\n\nyour paper address subitem 7a-i?\n\nCopy and paste relevant sections from manuscript title (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer Does your paper address CONSORT subitem 7b? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nNo.\n\nDoes your paper address CONSORT subitem 8a? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study No. Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nNo.\n\nDoes your paper address CONSORT subitem 9? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nNo.\n\nDoes your paper address CONSORT subitem 10? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nNo.\n\n11a-i) Specify who was blinded, and who wasn't Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).\n\nhttps://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2\u2026  21/33\n\nsubitem not at all important 1 2 3 4 5 essential 11b) If relevant, description of the similarity of interventions (this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention) 12a) Statistical methods used to compare groups for primary and secondary outcomes NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed Does your paper address subitem 11a-i? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nThe \"Experiment and data\" section.\n\n11a-ii) Discuss e.g., whether participants knew which intervention was the \"intervention of interest\" and which one was the \"comparator\"\n\nInformed consent procedures (4a-ii) can create biases and certain expectations -discuss e.g., whether participants knew which intervention was the \"intervention of interest\" and which one was the \"comparator\".\n\nDoes your paper address subitem 11a-ii?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer Does your paper address CONSORT subitem 11b? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nNo.\n\nDoes your paper address CONSORT subitem 12a? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nThe \"Method\" section.\n\nhttps://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2\u2026  22/33 subitem not at all important 1 2 3 4 5 essential 12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under \"Methods\"] (not a CONSORT item) subitem not at all important 1 2 3 4 5 essential 12a-i) Imputation techniques to deal with attrition / missing values\n\nImputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic  [4] ).\n\nDoes your paper address subitem 12a-i? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nNo.\n\nDoes your paper address CONSORT subitem 12b? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nNo.\n\nX26-i) Comment on ethics committee approval Does your paper address subitem X26-i?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2\u2026  23/33 subitem not at all important 1 2 3 4 5 essential subitem not at all important 1 2 3 4 5 essential RESULTS 13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center 13b) For each group, losses and exclusions after randomisation, together with reasons x26-ii) Outline informed consent procedures Outline informed consent procedures e.g., if consent was obtained o ine or online (how? Checkbox, etc.?) , and what information was provided (see 4a-ii). See  [6]  for some items to be included in informed consent documents.\n\nDoes your paper address subitem X26-ii?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer X26-iii) Safety and security procedures Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline) Does your paper address subitem X26-iii?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer Does your paper address CONSORT subitem 13a? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2\u2026  24/33 subitem not at all important 1 2 3 4 5 essential 14a) Dates de ning the periods of recruitment and follow-up subitem not at all important 1 2 3 4 5 essential 14b) Why the trial ended or was stopped (early) Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT ow diagram) *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study 13b-i) Attrition diagram Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other gures or tables demonstrating usage/dose/engagement.\n\nDoes your paper address subitem 13b-i?\n\nCopy and paste relevant sections from the manuscript or cite the gure number if applicable (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer Does your paper address CONSORT subitem 14a? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nNo.\n\n14a-i) Indicate if critical \"secular events\" fell into the study period Indicate if critical \"secular events\" fell into the study period, e.g., signi cant changes in Internet resources available or \"changes in computer hardware or Internet delivery resources\" Does your paper address subitem 14a-i?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer 15) A table showing baseline demographic and clinical characteristics for each group NPT: When applicable, a description of care providers (case volume, quali cation, expertise, etc.) and centers (volume) in each group subitem not at all important 1 2 3 4 5 essential 16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups subitem not at all important 1 2 3 4 5 essential Does your paper address CONSORT subitem 14b? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nNo.\n\nDoes your paper address CONSORT subitem 15? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study Table  1 ."
    },
    {
      "title": "15-i) Report demographics associated with digital divide issues",
      "text": "In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.\n\nyour paper address subitem 15-i? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study Table  1 .\n\n16-i) Report multiple \"denominators\" and provide de nitions Report multiple \"denominators\" and provide de nitions: Report N's (and effect sizes) \"across a range of study participation [and use] thresholds\" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants \"used\" the intervention/comparator at speci c pre-de ned time points of interest (in absolute and relative numbers per group). Always clearly de ne \"use\" of the intervention."
    },
    {
      "text": ") Level of human involvement in the METHODS section of the ABSTRACT"
    },
    {
      "text": "Note: In traditional o ine trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use \"blinded\" or \"unblinded\" to indicated the level of blinding instead of \"open\", as \"open\" in web-based trials usually refers to \"open access\" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)"
    },
    {
      "text": "(Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it) address subitem 1b-iv?"
    },
    {
      "text": "https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2\u2026 10INTRODUCTION: Speci c objectives or hypotheses METHODS 3a) Description of trial design (such as parallel, factorial) including allocation ratio 3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons 2a-ii) Scienti c background, rationale: What is known about the (type of) systemScienti c background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this speci c study, from which stakeholder viewpoint is the study performed, potential impact of ndings[2]. Brie y justify the choice of the comparator."
    },
    {
      "text": "interventions for each group with su cient details to allow replication, including how and when they were actually address subitem 4b-i? *"
    },
    {
      "text": "address subitem 5-ii?"
    },
    {
      "text": "changes to trial outcomes after the trial commenced, with reasons 6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed[9]."
    },
    {
      "text": "8b) Type of randomisation; details of any restriction (such as blocking and block size) 9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned 10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions 11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment subitem not at all important address CONSORT subitem 8b? *"
    },
    {
      "text": "Figure 3."
    },
    {
      "text": "Figure 3."
    },
    {
      "text": "//docs.google.com/forms/"
    },
    {
      "text": "subitem not at all important 1 2 3 4 5 essential 17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% con dence interval)\n\nsubitem not at all important 1 2 3 4 5 essential Does your paper address subitem 16-i? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nThe \"Analysis for objective 3\" and \"Objective 3\" section 16-ii) Primary analysis should be intent-to-treat Primary analysis should be intent-to-treat, secondary analyses could include comparing only \"users\", with the appropriate caveats that this is no longer a randomized sample (see 18-i).\n\nDoes your paper address subitem 16-ii?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer Does your paper address CONSORT subitem 17a? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nNo.\n\n17a-i) Presentation of process outcomes such as metrics of use and intensity of use\n\nIn addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational de nitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as \"average session length\". These must be accompanied by a technical description how a metric like a \"session\" is de ned (e.g., timeout after idle time)  [1]  (report under item 6a)."
    },
    {
      "title": "Does your paper address subitem 17a-i?",
      "text": "Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study Your answer No."
    },
    {
      "title": "18-i) Subgroup analysis of comparing only users",
      "text": "A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).\n\nyour paper address subitem 18-i?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer Does your paper address CONSORT subitem 19? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nNo."
    },
    {
      "title": "Does your paper address subitem 19-ii?",
      "text": "Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer 22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)\n\nRestate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use). Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study \"Principal results\" section."
    },
    {
      "title": "22-ii) Highlight unanswered new questions, suggest future research",
      "text": "Highlight unanswered new questions, suggest future research."
    },
    {
      "title": "Does your paper address subitem 22-ii?",
      "text": "Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer"
    },
    {
      "title": "20-i) Typical limitations in ehealth trials",
      "text": "Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events."
    },
    {
      "title": "Does your paper address subitem 20-i? *",
      "text": "Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study \"Limitations\" section Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer 21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting."
    },
    {
      "title": "Does your paper address subitem 21-ii?",
      "text": "Copy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study\n\nYour answer Does your paper address CONSORT subitem 23? *\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study Because this trial was conducted in India, it was not registered. This study is not funded.\n\nX27-i) State the relation of the study team towards the system being evaluated\n\nIn addition to the usual declaration of interests ( nancial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.\n\nyour paper address subitem X27-i?\n\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie y explain why the item is not applicable/relevant for your study"
    },
    {
      "title": "Your answer",
      "text": "As a result of using this checklist, did you make changes in your manuscript? * STOP -Save this form as PDF before you click submit\n\nTo generate a record that you lled in this form, we recommend to generate a PDF of this page (on a Mac, simply select \"print\" and then select \"print as PDF\") before you submit it.\n\nWhen you submit your (revised) paper to JMIR, please upload the PDF as supplementary le.\n\nDon't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you! Final step: Click submit !\n\nClick submit so we have your answers in our database! What were the most important changes you made as a result of using this checklist?"
    }
  ],
  "figures": [
    {
      "description": ") Level of human involvement in the METHODS section of the ABSTRACT"
    },
    {
      "description": "Note: In traditional o ine trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use \"blinded\" or \"unblinded\" to indicated the level of blinding instead of \"open\", as \"open\" in web-based trials usually refers to \"open access\" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)"
    },
    {
      "description": "(Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it) address subitem 1b-iv?"
    },
    {
      "description": "https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2\u2026 10INTRODUCTION: Speci c objectives or hypotheses METHODS 3a) Description of trial design (such as parallel, factorial) including allocation ratio 3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons 2a-ii) Scienti c background, rationale: What is known about the (type of) systemScienti c background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this speci c study, from which stakeholder viewpoint is the study performed, potential impact of ndings[2]. Brie y justify the choice of the comparator."
    },
    {
      "description": "interventions for each group with su cient details to allow replication, including how and when they were actually address subitem 4b-i? *"
    },
    {
      "description": "address subitem 5-ii?"
    },
    {
      "description": "changes to trial outcomes after the trial commenced, with reasons 6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed[9]."
    },
    {
      "description": "8b) Type of randomisation; details of any restriction (such as blocking and block size) 9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned 10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions 11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment subitem not at all important address CONSORT subitem 8b? *"
    },
    {
      "caption": "Figure 3 .",
      "description": "Figure 3."
    },
    {
      "description": "Figure 3."
    }
  ],
  "num_figures": 10,
  "num_citations": 4,
  "notes": [
    "[submission] submitted to /"
  ],
  "processing_software": {
    "GROBID": "0.8.2"
  }
}
